Pay in 4 interest-free payments of $5.95 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Duration of treatment varies based on condition severity and individual response
What to know about retatrutide Eli Lilly and Company (2026) 4
In studies, patients with obesity or overweight conditions have experienced an average weight loss ranging from 10% to 15% of their initial body weight over a period of several months
Retatrutide is an investigational triple-hormone receptor agonist developed by Eli Lilly that targets three receptors: GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon
01751-7/asset/f8ffb968-301f-4b4c-9c56-cfb01106603a/main.assets/gr2a_lrg.jpg)
A highly educated, high-quality professional team has been built
Micheroli R, Tellenbach C, Scherer A et al (2020) Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the swiss clinical quality management cohort
